149 related articles for article (PubMed ID: 25227788)
1. Hsp90 inhibitor geldanamycin enhances the antitumor efficacy of enediyne lidamycin in association with reduced DNA damage repair.
Han FF; Li L; Shang BY; Shao RG; Zhen YS
Asian Pac J Cancer Prev; 2014; 15(17):7043-8. PubMed ID: 25227788
[TBL] [Abstract][Full Text] [Related]
2. Non-caspase-mediated apoptosis contributes to the potent cytotoxicity of the enediyne antibiotic lidamycin toward human tumor cells.
Wang Z; He Q; Liang Y; Wang D; Li YY; Li D
Biochem Pharmacol; 2003 Jun; 65(11):1767-75. PubMed ID: 12781328
[TBL] [Abstract][Full Text] [Related]
3. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Liu H; Li L; Li XQ; Liu XJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
[TBL] [Abstract][Full Text] [Related]
4. Enediyne lidamycin induces apoptosis in human multiple myeloma cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase.
Zhen YZ; Lin YJ; Shang BY; Zhen YS
Int J Hematol; 2009 Jul; 90(1):44-51. PubMed ID: 19468799
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
[TBL] [Abstract][Full Text] [Related]
6. Lidamycin induces marked G2 cell cycle arrest in human colon carcinoma HT-29 cells through activation of p38 MAPK pathway.
Liu X; Bian C; Ren K; Jin H; Li B; Shao RG
Oncol Rep; 2007 Mar; 17(3):597-603. PubMed ID: 17273739
[TBL] [Abstract][Full Text] [Related]
7. EZH2 mediates lidamycin-induced cellular senescence through regulating p21 expression in human colon cancer cells.
Sha MQ; Zhao XL; Li L; Li LH; Li Y; Dong TG; Niu WX; Jia LJ; Shao RG; Zhen YS; Wang Z
Cell Death Dis; 2016 Nov; 7(11):e2486. PubMed ID: 27882937
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.
Pan Y; Ren KH; He HW; Shao RG
Cancer Biol Ther; 2009 Aug; 8(16):1559-66. PubMed ID: 19502782
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
Chen J; Ouyang ZG; Zhang SH; Zhen YS
Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
[TBL] [Abstract][Full Text] [Related]
11. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
12. [Effect of lidamycin on mitochondria initiated apoptotic pathway in human cancer cells].
Qiu Q; Wang Z; Jiang JM; Li DD
Yao Xue Xue Bao; 2007 Feb; 42(2):132-8. PubMed ID: 17518039
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of hsp90 compromises the DNA damage response to radiation.
Dote H; Burgan WE; Camphausen K; Tofilon PJ
Cancer Res; 2006 Sep; 66(18):9211-20. PubMed ID: 16982765
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells.
Li YP; Chen JJ; Shen JJ; Cui J; Wu LZ; Wang Z; Li ZR
Cancer Chemother Pharmacol; 2015 Apr; 75(4):773-82. PubMed ID: 25681003
[TBL] [Abstract][Full Text] [Related]
15. The HSP90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma.
Hu Y; Bobb D; He J; Hill DA; Dome JS
Cancer Biol Ther; 2015; 16(6):949-57. PubMed ID: 25920748
[TBL] [Abstract][Full Text] [Related]
16. [Synergistic effect and its possible mechanisms of lidamycin in combination with TRAIL in NSCLC].
Yang J; Chen SZ
Yao Xue Xue Bao; 2010 Oct; 45(10):1247-53. PubMed ID: 21348302
[TBL] [Abstract][Full Text] [Related]
17. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1.
Sugimoto K; Sasaki M; Isobe Y; Tsutsui M; Suto H; Ando J; Tamayose K; Ando M; Oshimi K
Oncogene; 2008 May; 27(22):3091-101. PubMed ID: 18071310
[TBL] [Abstract][Full Text] [Related]
18. Apoptotic Melanoma B16-F1 Cells Induced by Lidamycin Could Initiate the Antitumor Immune Response in BABL/c Mice.
Yang JL; Qin Y; Li L; Cao CY; Wang Q; Li Q; Lv YF; Wang Y
Oncol Res; 2016 Jan; 23(1-2):79-86. PubMed ID: 26802654
[TBL] [Abstract][Full Text] [Related]
19. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.
Koll TT; Feis SS; Wright MH; Teniola MM; Richardson MM; Robles AI; Bradsher J; Capala J; Varticovski L
Mol Cancer Ther; 2008 Jul; 7(7):1985-92. PubMed ID: 18645008
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of lidamycin on hepatoma and active moiety of its molecule.
Huang YH; Shang BY; Zhen YS
World J Gastroenterol; 2005 Jul; 11(26):3980-4. PubMed ID: 15996019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
